Marisi, G.; Petracci, E.; Raimondi, F.; Faloppi, L.; Foschi, F.G.; Lauletta, G.; Iavarone, M.; Canale, M.; Valgiusti, M.; Neri, L.M.;
et al. ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers 2019, 11, 1023.
https://doi.org/10.3390/cancers11071023
AMA Style
Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM,
et al. ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers. 2019; 11(7):1023.
https://doi.org/10.3390/cancers11071023
Chicago/Turabian Style
Marisi, Giorgia, Elisabetta Petracci, Francesco Raimondi, Luca Faloppi, Francesco Giuseppe Foschi, Gianfranco Lauletta, Massimo Iavarone, Matteo Canale, Martina Valgiusti, Luca Maria Neri,
and et al. 2019. "ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib" Cancers 11, no. 7: 1023.
https://doi.org/10.3390/cancers11071023
APA Style
Marisi, G., Petracci, E., Raimondi, F., Faloppi, L., Foschi, F. G., Lauletta, G., Iavarone, M., Canale, M., Valgiusti, M., Neri, L. M., Ulivi, P., Orsi, G., Rovesti, G., Vukotic, R., Conti, F., Cucchetti, A., Ercolani, G., Andrikou, K., Cascinu, S.,
... Casadei-Gardini, A.
(2019). ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers, 11(7), 1023.
https://doi.org/10.3390/cancers11071023